Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Beyond Air (NASDAQ:XAIR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.
Earnings & Valuation
This table compares Pulse Biosciences and Beyond Air”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $700,000.00 | 1,412.25 | -$42.21 million | N/A | N/A |
| Beyond Air | $3.02 million | 6.45 | -$60.24 million | ($1.06) | -0.27 |
Pulse Biosciences has higher earnings, but lower revenue than Beyond Air.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | N/A | -96.89% | -74.83% |
| Beyond Air | -1,730.00% | -226.01% | -109.75% |
Institutional and Insider Ownership
76.9% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 71.5% of Pulse Biosciences shares are owned by company insiders. Comparatively, 20.1% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Pulse Biosciences and Beyond Air, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| Beyond Air | 0 | 1 | 3 | 1 | 3.00 |
Beyond Air has a consensus price target of $3.67, suggesting a potential upside of 1,194.27%. Given Beyond Air’s stronger consensus rating and higher possible upside, analysts plainly believe Beyond Air is more favorable than Pulse Biosciences.
Summary
Pulse Biosciences beats Beyond Air on 8 of the 13 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
